Novo Nordisk built modern obesity pharmacology. Liraglutide came first in 2009, with Saxenda following in 2014. Semaglutide split into three products — Ozempic for type-2 diabetes, Wegovy for obesity, and Rybelsus as the oral form. The 2025 and 2026 cadence has been about defending that position against Lilly's tirzepatide while moving the next generation forward.
The May 6 Q1 2026 print landed strong: net sales DKK 96.82B (+24% YoY), operating profit DKK 59.62B (+54%). Wegovy pill drove the upside with DKK 2.26B (~$354M) in Q1 — almost 2× analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative since the January 5 launch. CEO Mike Doustdar told CNBC on May 6 that Wegovy holds 65% of all new US GLP-1 prescriptions, calling the moment a 'turnaround situation.' NovoCare priced the 1.5 mg starter at $149/month and moved the 4 mg dose from $149 to $199 effective April 15. On May 1, Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill at 1.5/4/9 mg with improved-absorption reformulation across 70,000+ pharmacies. Wegovy HD 7.2 mg launched April 7 with a STEP UP 21% mean weight loss anchor. Full-year guidance tightened to a 4–12% sales-and-operating-profit decline (from the prior 5–13%) — Jefferies pushed back that the lower-end guidance was not lifted enough to be a positive surprise.
The pipeline gets harder from here. CagriSema (cagrilintide + semaglutide) failed to match Zepbound in February's head-to-head readout (23% vs 25.5%), and the Q1 documents disclosed Novo has discontinued the single-chamber co-formulation device — the dual-chamber injectable system continues with the original FDA filing already submitted and a higher-dose Phase 3 trial slated for H2 2026. Petrelintide and amycretin-prodrug sit further back. The Indian semaglutide patent expired in March 2026 and licensed generics from Biocon and Dr. Reddy's followed within weeks.
Novo Nordisk's CagriSema REDEFINE 1 treatment-target analysis presented as an oral presentation at ECO 2026 on May 12 reported that the cagrilintide + semaglutide combination drove a higher percentage of participants to clinically meaningful BMI and waist-to-height ratio (WHtR) targets than any monotherapy or placebo arm. 50.7% of CagriSema-treated participants reached BMI <30 at week 68 vs 10.2% on placebo, and participants reaching BMI <27 plus WHtR <0.53 showed normalization of cardiometabolic parameters at higher rates than non-achievers. A companion REDEFINE 1 cardiovascular risk analysis scheduled for May 14 ECO presentation tracks predicted atherosclerotic CVD risk reduction. The data complements the May 12 body-composition substudy (35.7% fat-mass loss vs 14.4% lean tissue loss).
Sector stock reaction across May 12-13: Novo Nordisk ADRs popped roughly 6% premarket May 12 on the early-responder + women's-data combination and the OASIS 4 mobility analyses; Eli Lilly traded flat as the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN dual publication confirmed expected maintenance positioning rather than producing fresh upside surprises. Analysts noted the broader 'long-term treatment' thesis — that GLP-1 obesity drugs are chronic-disease medications, not short courses — got concrete trial backing this week between SURMOUNT-MAINTAIN, ATTAIN-MAINTAIN, and STEP UP early-responder analyses. The week's narrative shift sets up the May 14-15 ECO Day 3+4 cycle and the May 29-June 2 ASCO 2026 meeting in Chicago — where peptide-drug conjugates (Bicycle BT8009, Avacta AVA6000, Pfizer FAP-Dox) take the next round of clinical-data spotlights.
A post-hoc analysis of the Phase 3 STEP UP trial presented Tuesday May 12 at ECO 2026 identified an 'early responder' subgroup — patients who lost at least 15% body weight within the first 24 weeks. About 27% of patients on the higher-dose Wegovy 7.2 mg dose met that threshold vs 21% on the 2.4 mg dose and 3% on placebo. Early responders went on to lose a mean 27.7% body weight at week 72 (vs the 21% headline mean across all 7.2 mg patients). The analysis also confirmed that 84% of weight loss across both Wegovy doses came from fat mass, with muscle function preserved. The data sharpens the case for early-response-based dose decisions in the post-launch real-world workflow.
A second post-hoc analysis of STEP UP presented Tuesday found Wegovy 7.2 mg delivered consistent weight loss across reproductive life stages: 22.6% premenopausal, 19.7% perimenopausal, 19.8% postmenopausal, with 41.4% of premenopausal women hitting ≥25% loss. Waist-circumference reductions: 17.5%, 15.6%, 15.3% respectively. Separately, a real-world analysis of 34,000+ women showed that those taking Wegovy had a 42-45% lower migraine risk and a 25% lower depression risk starting six months in versus those on menopausal hormone therapy alone. The real-world data lands as observational signals that warrant prospective study — not as proof of causation — but reinforces the cardiovascular and quality-of-life narrative for the women's-health subgroup.
A prespecified body-composition substudy of REDEFINE 1 presented at ECO 2026 reported that 252 participants on CagriSema 2.4 mg/2.4 mg (semaglutide + cagrilintide) achieved a 35.7% relative reduction in fat mass and a 14.4% reduction in lean soft-tissue mass at week 68 — compared with 5.7% and 4.3% on placebo. The headline 22.7% mean weight reduction in REDEFINE 1 (NEJM publication June 2025) thus broke down with a fat-mass-to-lean-tissue ratio of roughly 2.5:1, a more favorable body-composition profile than the typical 1.5-2:1 ratio reported for GLP-1 monotherapy. The data builds the case for combination amylin-GLP-1 therapy as preferentially fat-selective.
Hims & Hers reported Q1 2026 after market close May 11: revenue $608.1M (+4% YoY vs $586M prior year), missing the $616.9M consensus; subscribers up 9% to 2.6M; net loss of $92.1M ($0.41/share) vs $49.5M net income in Q1 2025. Gross margin compressed from 73% to 65% on the strategic pivot away from compounded semaglutide toward branded Novo Nordisk Wegovy/Ozempic supply (live since March 26). Q1 closed March 31 — meaningful Wegovy revenue contribution lands in Q2. Full-year 2026 guidance was raised: revenue to $2.8-3.0B and Adjusted EBITDA to $275-350M. The company is keeping limited compounded GLP-1 access alive alongside branded supply, threading the FDA April 30 503B bulks-list proposal.
Prof. Luca Busetto (University of Padova) and colleagues will present at ECO 2026 a pooled subgroup analysis of 358 adults aged 65 and older (mean age 69, 72% women) drawn from STEP 1, 3, 4, 5, 8, and 9 — 248 received semaglutide 2.4 mg, 110 placebo. The semaglutide arm lost 15.4% body weight on average vs 5.1% on placebo; 46.8% of semaglutide users hit ≥15% weight loss vs 6.4% on placebo, and 28.6% reached ≥20% vs 2.7%. Waist circumference fell 14.3 cm vs 6.0 cm. 27% on semaglutide reached a healthy BMI (<27) vs 5.5%. Serious adverse events occurred in 19.0% on semaglutide vs 12.7% on placebo. The analysis complements Lilly's ECO 2026 orforglipron 65+ subgroup analysis from ATTAIN-1 and ATTAIN-2 — both filling the geriatric data gap for the first generation of mainstream obesity drugs.
Health Canada announced May 1 approval of a second generic semaglutide injection, filed by Canadian-based Apotex as a generic version of Novo Nordisk's Ozempic. The April 28, 2026 first approval (Dr. Reddy's Laboratories) was followed three days later by the Apotex green light, making Canada the first G7 country with two approved generic semaglutide products. Health Canada is currently reviewing seven additional generic submissions. Patent context: Canadian patent protection lapsed earlier than expected after a Novo Nordisk maintenance-fee issue. Sandoz separately targets a Q3 2026 commercial launch and the company has projected 45-90% price reductions versus brand-name Ozempic. US patent protection runs through December 2031.
Hims & Hers reports Q1 2026 after market close May 11, with consensus revenue at $616-619M and EPS at roughly 3-4 cents — a 90% YoY decline. The investor question is whether the legitimate Wegovy/Ozempic distribution channel from the Novo Nordisk partnership (signed April 2026) can offset the wind-down of the compounded semaglutide business. Novo's branded products were not on the platform until March 26, with Q1 books closing March 31 — meaningful Wegovy revenue contribution likely lands in Q2. Subscriber count above 2.5M and ~82% three-month retention remain the standing benchmarks. The April 30 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list raises the medium-term bar for any compounding-driven model.
A Frontiers in Endocrinology multicenter retrospective cohort study (2026) reports real-world safety and effectiveness of semaglutide in patients with type 2 diabetes and end-stage renal disease — the population systematically excluded from FLOW (which capped at eGFR ≥ 25) and the SELECT pre-specified kidney composite analysis. ESRD patients comprise roughly 1% of the diabetic population but 7% of US healthcare spending; their cardiovascular event rates are among the highest documented. The cohort fills a clinical gap: prescribers managing dialysis-dependent patients have had to extrapolate from outcome trials that explicitly excluded the population. Work joins the SOUL oral-semaglutide CKD analysis as the fastest-growing GLP-1 evidence stream beyond obesity and T2D.
Novo Nordisk CEO Mike Doustdar told CNBC May 6 that the Wegovy brand now holds 65% of all new US GLP-1 prescriptions and characterized the moment as a 'turnaround situation' for the franchise. The Q1 print also disclosed that Novo has terminated the single-chamber CagriSema co-formulation project 'due to portfolio considerations' — the dual-chamber injectable system continues, with the original FDA filing already submitted and a decision expected late 2026. The CEO insisted plans for the CagriSema launch remain on track despite the device change. CNBC also documented LifeMD's new-patient volume jumping from 300–400/day before the Wegovy pill launch to 600–1,000/day after.
Jefferies analysts pushed back May 6 against the otherwise-positive market reaction to Novo Nordisk's Q1, arguing that the change in full-year guidance (tightened from a 5–13% sales-and-operating-profit decline to a 4–12% decline) was unlikely to lift consensus forecasts and could even contract them: 'we suspect the fact that the company has not lifted the lower end of the guidance range more will be seen as a negative.' The framing matters because NVO US-listed shares had already risen ~6% on the print, and the price-war pressure on the GLP-1 class — with Wegovy pill running at $149/month for the 1.5 mg starter dose against intensifying Foundayo competition — leaves the lower-end risk path open through year-end.
CNBC's May 6 Wegovy-Q1 piece documented LifeMD new-patient volume jumping from 300–400 per day before the Wegovy pill January 5 launch to 600–1,000 per day after, with the telehealth platform crediting the pill format and improved insurance coverage for unlocking a wave of GLP-1-curious patients who had not previously committed to injectables. LifeMD has been one of the most exposed independent pure-play telehealth obesity platforms during the Novo channel-expansion era, and its data point feeds the broader 'oral GLP-1 expands the market' thesis that Lilly's Foundayo team also referenced on the April 30 Q1 call (where 80% of Foundayo patients were new to the GLP-1 class).
Novo Nordisk reported Q1 2026 results May 6: net sales of DKK 96.82B (+24% YoY) and operating profit of DKK 59.62B (+54%). The Wegovy pill drove the print with DKK 2.26B (~$354M) in Q1 sales — almost double the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and more than 2 million cumulative US prescriptions since the January 5 launch. Injectable Wegovy sales rose 12% YoY to DKK 18.2B. Ozempic sales fell 8% YoY but came in above expectations. The company tightened full-year guidance to a 4–12% sales-and-operating-profit decline at constant exchange rates, narrower than the prior 5–13% range. NVO US-listed shares rose roughly 6% on the print.
Novo Nordisk's Q1 print clarified that Wegovy HD (semaglutide 7.2 mg injection) — approved by the FDA in March and launched in the US on April 7 — is contributing to the premium-tier injectable mix alongside the standard 2.4 mg dose. The STEP UP trial showed 21% mean weight loss at 72 weeks if all patients stayed on treatment (19% regardless), with 89% on 7.2 mg achieving ≥5% body-weight reduction versus 38% with placebo. The label requires four-plus weeks of tolerability on semaglutide 2.4 mg before stepping up. NovoCare prices the 7.2 mg dose at $399/month self-pay and as low as $25 for many commercially insured patients via the savings offer. Dysesthesia at 22% on 7.2 mg vs. 6% on 2.4 mg and 0.3% on placebo is the only meaningful safety signal beyond the broader GLP-1 class.
Novo Nordisk confirmed in its Q1 2026 commentary that a higher-dose CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) Phase 3 trial will start in the second half of 2026, in response to the February 23 readout where the lower-dose 2.4/2.4 mg arm achieved 23% mean weight loss vs. 25.5% on tirzepatide 15 mg over 84 weeks — failing the non-inferiority primary endpoint. The original CagriSema FDA filing is already submitted with a decision expected in late 2026; the higher-dose program is meant to position Novo for a more competitive head-to-head against tirzepatide before the retatrutide TRIUMPH readouts arrive. ECO 2026 in Istanbul (May 12–15) will deliver additional CagriSema data alongside Wegovy 7.2 mg.
Reuters reported May 5 that Novo Nordisk's Wegovy pill posted roughly 721,000 US prescriptions in Q1 per IQVIA, beating analyst expectations on volume but raising margin questions: about 450,000 of those scripts were for the cheapest 1.5 mg starter dose at $149/month. Lilly's Foundayo approval in early April closed Novo's window as the only oral obesity pill, and Wegovy injection prices have fallen rapidly amid intensifying competition. The Danish company's market value has shed more than $400 billion from its 2024 peak. Wednesday's Q1 print (May 6, 7:30 CEST) is the test: investors are watching whether Novo holds February's guidance of a 5–13% sales and operating-profit decline at constant exchange rates, and whether direct-to-consumer NovoCare and the WW Med+ + GoodRx channels can offset price pressure.
Novo Nordisk announced May 1 that Rybelsus is being retired as a US brand and the molecule re-launches Monday May 4 as Ozempic Pill at 1.5/4/9 mg in 70,000+ pharmacies. Bloomberg and Fierce Pharma framed it as a marketing-driven move: same active ingredient as Rybelsus, but reformulated for improved absorption and bioavailability so smaller tablets achieve equivalent efficacy. Aligning the oral and injectable products under a single brand is meant to simplify prior authorizations and prescribing discussions, and to capitalize on Ozempic's recognition as Novo defends market share against Lilly's Foundayo. Rybelsus continues outside the US.